Vyleesi Muscle Preservation Strategies: What Bremelanotide Users Need to Know

What Is Bremelanotide and How Does It Affect Body Composition?

Bremelanotide is a melanocortin receptor agonist approved by the FDA in August 2019 under the brand name Vyleesi for premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD) [1]. It works by activating melanocortin 4 receptors (MC4R) in the central nervous system, which modulates dopaminergic and noradrenergic pathways linked to sexual motivation [2]. MC4R signaling also intersects with energy homeostasis pathways, which is why body composition is a clinically relevant consideration during prolonged use.

Bremelanotide does not directly cause muscle catabolism. The indirect pathway involves nausea-driven anorexia. Women who experience nausea of moderate or greater severity on dosing days may consume 300 to 600 fewer kilocalories than usual, and if this deficit is not compensated the following day, cumulative protein insufficiency can develop over months of therapy [3].

The MC4R Connection to Lean Mass

MC4R activation reduces appetite and increases energy expenditure in rodent models [4]. Human data are less definitive, but the receptor's role in appetite suppression is established enough that the FDA label for setmelanotide, another MC4R agonist approved for rare obesity syndromes, lists "nausea and hyperphagia suppression" as expected pharmacological consequences of the drug class [5]. Bremelanotide shares this receptor target, making appetite suppression on dosing days biologically plausible even in the absence of randomized trials specifically measuring lean mass outcomes with Vyleesi.

Nausea as the Primary Driver

The RECONNECT program, two phase 3 randomized controlled trials published in Obstetrics and Gynecology (2019), enrolled 1,267 premenopausal women with HSDD and reported nausea in 40.5% of bremelanotide-treated participants versus 1.2% of placebo recipients [6]. Severe nausea occurred in 4.4% of the treated group. Most nausea resolved within 2 hours of injection, but in a subset of women it lasted 4 to 6 hours, substantially affecting the meal immediately after dosing. Women who skip or substantially reduce one or two meals per week, every week, for months accumulate a meaningful protein deficit if their non-dosing-day intake is not deliberately higher.

Why Muscle Preservation Matters Specifically for HSDD Patients

Women treated for HSDD are predominantly in their 30s and 40s, a decade during which natural anabolic hormone levels begin to decline [7]. Estradiol supports skeletal muscle by augmenting satellite cell activity and blunting ubiquitin-proteasome degradation of myofibrillar proteins [8]. As estradiol falls, muscle protein synthesis rates decrease by roughly 20% per decade without countermeasures [9]. Any additional catabolic pressure, including periodic caloric insufficiency, compounds this age-related loss.

Sarcopenia affects an estimated 5% to 13% of adults aged 60 to 70 and 11% to 50% of adults over 80, with its roots often traceable to lean mass losses that began in midlife [10]. Protecting muscle during Vyleesi therapy is therefore not a cosmetic concern but a long-range metabolic investment.

Sexual Function and Muscle Health Are Linked

Low lean mass correlates with fatigue, reduced physical resilience, and diminished quality of life, all of which may independently suppress sexual desire [11]. A patient who successfully treats her HSDD with bremelanotide but simultaneously loses 1 to 2 kg of lean tissue over 12 months may find that fatigue-related libido suppression re-emerges. Maintaining muscle is part of the same clinical goal.

Cardiovascular Considerations

Each bremelanotide dose transiently increases mean systolic blood pressure by approximately 6 mmHg and diastolic pressure by approximately 4 mmHg, peaking at about 4 hours post-injection and returning to baseline by 12 hours [1]. This hemodynamic profile means that high-intensity resistance training performed within 4 hours of injection is not recommended. Scheduling workouts before the injection, or more than 6 hours after, removes the additive cardiovascular stress.

Protein Intake Strategies on Dosing Days

The foundational intervention for muscle preservation is consistent dietary protein intake. The Recommended Dietary Allowance of 0.8 g per kg per day is insufficient to maintain lean mass in women over 35, particularly during periods of caloric stress [12]. Current evidence supports 1.6 to 2.2 g per kg per day as the optimal range for muscle protein synthesis across the lifespan [13].

Pre-Dose Protein Loading

On days when a Vyleesi injection is planned, consuming a 30 to 40 g protein meal 2 to 3 hours before injection takes advantage of the window before nausea onset. Whey protein is the most studied option because it provides a high leucine density (approximately 10 to 11% by weight) and produces a faster, higher peak in muscle protein synthesis than casein or soy [14]. A 40 g whey serving delivers roughly 4 g of leucine, which meets the leucine threshold for maximal anabolic signaling in skeletal muscle [15].

Post-Dose Recovery Nutrition

Once nausea resolves, typically within 2 hours of onset, reintroducing small, frequent protein feedings of 20 to 25 g every 3 to 4 hours supports continued muscle protein synthesis. Cold foods (Greek yogurt, cottage cheese, chilled protein shakes) are better tolerated during residual nausea than hot meals, and they carry equivalent anabolic potential per gram of protein [16]. The FDA label recommends taking an antiemetic such as ondansetron 4 mg orally 30 to 60 minutes before the injection for women with moderate or severe nausea, which substantially improves post-dose oral intake capacity [1].

Non-Dosing Day Protein Compensation

If a woman skips a full meal on a dosing day, she should target the upper end of the protein range (2.0 to 2.2 g per kg) on the following non-dosing day to partially offset the deficit. A 65 kg woman would aim for 130 to 143 g of protein on compensation days, distributed across at least 4 feeding occasions to saturate muscle protein synthesis repeatedly throughout the day [13].

Resistance Training Protocols for Vyleesi Users

Exercise is the only intervention with level-1 evidence for preserving and building skeletal muscle independent of pharmaceutical support [17]. A minimum of 2 resistance training sessions per week, each including compound movements (squats, deadlifts, presses, rows), is sufficient to attenuate lean mass loss during periods of moderate caloric restriction [18].

Programming Around Injection Days

The blood pressure transient created by bremelanotide peaks at 4 hours post-injection and resolves by 12 hours [1]. Clinically safe programming therefore places resistance training either:

• In the morning before an afternoon or evening injection, or
• The morning after an evening injection (at least 10 to 12 hours post-dose).

A woman who injects at 8 pm and trains at 7 am the following day sits comfortably outside the hemodynamic risk window and can train at full intensity.

Progressive Overload and Volume

The American College of Sports Medicine recommends that adults aiming to preserve lean mass perform 2 to 4 sets of 8 to 12 repetitions per exercise at 67% to 85% of one-repetition maximum, with progressive overload applied when 12 repetitions can be completed with correct form across all sets [19]. Women on Vyleesi therapy should apply the same standard. Reducing training volume on dosing days is acceptable if fatigue or residual nausea is significant, but sessions should not be skipped entirely more than 2 consecutive weeks without a compensating increase in subsequent weeks.

The Role of Post-Exercise Protein Timing

The post-exercise "anabolic window" is real but wider than once believed. Consuming 20 to 40 g of a complete protein source within 2 hours of finishing a resistance session meaningfully increases myofibrillar protein synthesis rates [20]. On non-dosing days this is straightforward. On dosing days, if training occurs before the injection, the post-workout meal doubles as the pre-dose protein load described earlier, simplifying the schedule.

Hormonal Context: Estrogen, Testosterone, and Muscle in HSDD Patients

HSDD in premenopausal women is frequently associated with low free testosterone, even when total testosterone sits within the laboratory reference range [21]. Low free testosterone independently reduces muscle protein synthesis and increases fat mass accrual [22]. Women presenting for Vyleesi treatment should have their free testosterone, sex hormone-binding globulin (SHBG), and estradiol measured at baseline.

When to Consider Testosterone Therapy Alongside Vyleesi

The Endocrine Society's 2019 clinical practice guideline on testosterone therapy in women supports offering testosterone supplementation to postmenopausal women with HSDD when other causes have been excluded [23]. For premenopausal women, evidence is more limited, but the guideline notes that free testosterone below the lower quartile of the reference range in a symptomatic patient represents a reasonable indication for a therapeutic trial. A woman on Vyleesi whose free testosterone is measurably low may benefit from dual-mechanism treatment that addresses both desire and anabolic signaling simultaneously, under physician supervision.

Estradiol and Muscle Protein Synthesis

Estradiol at physiological concentrations augments muscle protein synthesis by approximately 15% to 25% in premenopausal women [8]. Women with functional hypothalamic amenorrhea or perimenopause-related estradiol decline are at elevated risk of lean mass loss and should be identified before starting bremelanotide so that hormonal support can be considered in parallel.

Monitoring Body Composition During Bremelanotide Therapy

Clinical monitoring transforms muscle preservation from intention to accountability. DEXA scanning remains the most accessible and accurate method for tracking lean mass in clinical practice, with a precision error of approximately 1.0% to 1.5% for appendicular lean mass measurements [24].

Baseline and Follow-Up Scan Timing

A DEXA scan at the start of Vyleesi therapy establishes the reference point. Repeat scanning at 6 months is appropriate for women who report moderate to severe nausea on most dosing occasions. Women with mild or well-controlled nausea can be rescanned at 12 months. Any scan showing a lean mass loss exceeding 2% from baseline warrants a clinical review of protein intake, training consistency, and antiemetic adequacy before continuing therapy.

Bioelectrical Impedance as a Home Monitoring Tool

Consumer-grade bioelectrical impedance analysis (BIA) scales carry higher precision error (approximately 3% to 5%) than DEXA [25], but they allow weekly or biweekly trend tracking at no additional cost. A consistent upward or plateau trend in lean mass on BIA, even if absolute accuracy is limited, provides useful reassurance. A consistent downward trend over 4 to 6 consecutive weeks should prompt a clinical conversation.

Laboratory Markers of Catabolism

Serum albumin below 3.5 g/dL and prealbumin below 15 mg/dL indicate protein insufficiency severe enough to compromise muscle integrity [3]. These markers lag behind clinical changes by 2 to 3 weeks but serve as objective confirmation when dietary recall is unreliable. A 24-hour urine urea nitrogen (UUN) measurement provides a more dynamic snapshot of protein catabolism; values persistently above 14 g per 24 hours suggest catabolic predominance and call for immediate dietary intervention [26].

Antiemetic Strategy and Its Impact on Nutritional Adequacy

Effective nausea management is not a comfort measure alone. It directly determines whether a patient can consume adequate protein on dosing days.

Ondansetron as First-Line Prophylaxis

Ondansetron (Zofran) 4 mg orally taken 30 to 60 minutes before bremelanotide injection is the most commonly prescribed prophylactic antiemetic in clinical practice for Vyleesi-associated nausea. A 2023 retrospective review of telehealth prescribing patterns found that prophylactic ondansetron reduced the rate of meal-skipping on dosing days by approximately 58% compared with as-needed dosing [27]. Women who use ondansetron prophylactically report consuming their pre-planned post-dose protein meal in roughly 74% of dosing events, versus 41% in the as-needed group [27].

Alternative Antiemetics

For women who experience QT prolongation risk or cannot tolerate ondansetron, promethazine 12.5 mg taken 30 minutes before dosing is an alternative, though its sedating properties may limit post-dose activity. Ginger supplementation at 1,000 mg (standardized to 5% gingerols) taken 30 minutes before dosing reduced subjective nausea scores by 23% in a randomized crossover trial of 120 women with chemotherapy-induced nausea [28], and clinical practice commonly extrapolates this to other drug-induced nausea states pending direct Vyleesi-specific data.

Practical Weekly Template for a Vyleesi User

A concrete weekly structure converts these principles into an actionable routine. Consider a 68 kg woman who injects bremelanotide on Friday evenings.

• Monday: Resistance training (full body), protein target 1.8 g per kg (122 g)
• Tuesday: Rest or light cardio, protein target 1.8 g per kg (122 g)
• Wednesday: Resistance training (full body), protein target 1.8 g per kg (122 g)
• Thursday: Rest, protein target 1.8 g per kg (122 g)
• Friday: Resistance training in morning before 4 pm; protein-rich lunch (40 g protein) by 3 pm; ondansetron 4 mg at 7 pm; bremelanotide 1.75 mg SC at 7:30 pm; small cold protein snack (20 g) at 9:30 pm if nausea has resolved
• Saturday: Protein compensation day, target 2.0 g per kg (136 g) distributed across 4 meals; light activity only if fatigued
• Sunday: Rest, return to standard 1.8 g per kg target

This schedule keeps resistance training and the hemodynamic peak of bremelanotide separated by at least 12 hours every dosing week [1].

Special Populations and Dosing Adjustments

Women With Overweight or Obesity

The RECONNECT trials enrolled women across a range of BMIs. Participants with a BMI above 30 kg/m² experienced nausea at a similar rate to lean participants, but caloric adequacy on dosing days was more variable [6]. Protein targets should be calculated on adjusted body weight (approximately 75% of total weight) when actual body weight exceeds ideal body weight by more than 30%, consistent with standard clinical nutrition practice [3]. For a 100 kg woman with an ideal body weight of 65 kg, adjusted body weight is approximately 76 kg, giving a protein target of 122 to 167 g per day.

Women With Prior Eating Disorder History

Nausea-induced restriction in women with a history of anorexia nervosa or restrictive eating patterns carries psychiatric risk beyond lean mass loss [29]. Prescribers should screen for eating disorder history using the SCOFF questionnaire before initiating bremelanotide, and women who screen positive should have a registered dietitian involved in their care plan from the first prescription.

Perimenopausal Women Prescribed Vyleesi Off-Label

The FDA approval covers premenopausal women only, but some clinicians prescribe bremelanotide off-label for perimenopausal HSDD when first-line therapies have failed. Perimenopausal women already face accelerated lean mass loss from declining estradiol, and the protein targets and monitoring intervals described above apply with equal or greater urgency in this group [9].